Answers are grounded in this paper and cite their sources.
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) remain persistent human pathogens. Primary replication at epithelial surfaces gives way to neuronal invasion, lifelong latency and episodic reactivation, and animal models are needed to dissect that cycle and to rank vaccines, antivirals, gene-editing strategies and immunotherapies. No single model reproduces the full human disease spectrum, and recent species-oriented surveys have catalogued the available platforms without settling the question of readout transfer. Here, we identify species-specific divergence in viral immune-evasion proteins as a fundamental mechanistic barrier to direct extrapolation of readouts across hosts. We trace ICP0, ICP34.5, US3, UL36, UL37, vhs and latency-associated transcript (LAT)-encoded microRNAs to the cGAS-STING, Toll-like receptor and interferon nodes they antagonize. The comparison extends beyond whole animals to cultured neurons, organoids and humanized systems, clarifying why pharmacological quiescence in neuronal cultures differs from latency in vivo. From these constraints a model-selection framework is derived, its criteria are stated, and the framework is applied to a published vaccine result to show which claims the data can and cannot support. Mouse models give genetic access to Toll-like receptor, cGAS-STING, interferon, myeloid, T-cell and neuroinflammatory pathways; guinea pigs reproduce recurrent genital disease and spontaneous shedding; rabbits support ocular latency and reactivation; neonatal infection is treated as a separate endpoint set because it carries the highest rates of dissemination and central nervous system disease.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: